Wang, Hung-MingHung-MingWangPEI-JEN LOUYang, Muh-HwaMuh-HwaYangChen, Tein-HuaTein-HuaChenLien, Ming-YuMing-YuLienLin, Jin-ChingJin-ChingLinJO-PAI CHENLu, Wei-ChenWei-ChenLuLu, Hsueh-JuHsueh-JuLuHuang, Tai-LinTai-LinHuangYen, Chia-JuiChia-JuiYenWu, Shang-YinShang-YinWuWang, Hui-ChingHui-ChingWangHsieh, Meng-CheMeng-CheHsieh2024-02-232024-02-232024-0117762596https://scholars.lib.ntu.edu.tw/handle/123456789/639896Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs.en[SDGs]SDG3journal article10.1007/s11523-023-01028-7382850672-s2.0-85183363244https://api.elsevier.com/content/abstract/scopus_id/85183363244